PINK:SKYE
Skye Bioscience, Inc. Stock News
$12.05
-0.200 (-1.63%)
At Close: May 17, 2024
Skye Bioscience Responds to OTC Markets Promotional Policy
05:14pm, Friday, 08'th Dec 2023
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid syst
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endoca
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion
07:00am, Tuesday, 28'th Nov 2023
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
07:00am, Tuesday, 21'st Nov 2023
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address di
• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, Californ
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Tuesday, 05'th Sep 2023
San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid
Skye Bioscience hires ophthalmic-focused CRO for Phase 2a US trial of glaucoma and hypertension treatment
09:12am, Thursday, 02'nd Feb 2023
Skye Bioscience Inc (OTCQB:SKYE) has entered into an agreement with Lexitas Pharma Services Inc, a full-service ophthalmic-focused contract research organization (CRO) for its planned Phase 2a study o
Skye Bioscience gets positive safety review of SBI-100 OE after phase 1 first cohort
07:51am, Tuesday, 31'st Jan 2023
Skye Bioscience Inc (OTCQB:SKYE) said it has received a positive recommendation following a pre-specified data review by the safety review committee (SRC) based on dosing of the first cohort of eight
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
12:31pm, Tuesday, 20'th Dec 2022 InvestorsHub
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE Phase 2 clinical trial planned to start in H1 2023San Diego, California, December 20, 2022 -- InvestorsHub NewsWire -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration ("FDA") has given the okay to proceed for the Investi...
Skye Bioscience receives US FDA authorization of Investigational New Drug Application for SBI-100 OE
07:53am, Tuesday, 20'th Dec 2022
Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) application for SBI-100 Ophthalmic Emulsion (OE),�
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
12:57pm, Friday, 16'th Dec 2022 InvestorsHub
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion San Diego, California, December 16, 2022 -- InvestorsHub NewsWire -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Emulsion ("OE") in the first cohort of healthy participants in the single ascen...
Skye Bioscience Inc (OTCQB:SKYE) said it has completed dosing of SBI-100 Ophthalmic Emulsion (OE) in the first cohort of healthy participants in the single ascending dose (SAD) part of its Phase 1 stu
Skye Bioscience appoints Dr Chris Twitty as chief scientific officer
07:32am, Tuesday, 13'th Dec 2022
Skye Bioscience Inc (OTCQB:SKYE) said it has hired Dr Chris Twitty as the company's first chief scientific officer (CSO). With over 25 years of life science research and drug development experience,
Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
07:00am, Tuesday, 22'nd Nov 2022
San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid de
Skye Bioscience submits IND application for SBI-100 Ophthalmic Emulsion to US regulator
08:17am, Thursday, 17'th Nov 2022
Skye Bioscience Inc (OTCQB:SKYE) said it has submitted an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its SBI-100 Ophthalmic Emulsion (SBI-100 OE), whic